



가 14  
 , 가 110 70  
 (subdigastric lymph node dissection)  
 50 , (Supraomohyoid neck di-  
 ssection) 20 ,  
 (Modified radiacal neck dissection)  
 1  
 , ,  
 1988 6 2002 1 13 7 , 75  
 가  
 124 136 가  
 가 60 가 64  
 8 84 46 . SAS(V8.1)  
 Logistic regression  
 가 114 가 , 11 ,  
 4 , 1 360 Kaplan - Meier Log - Rank . p - value  
 . 2002 AJCC T1 가 0.05  
 31 , T2 48 , T3 33 , T4가 12 .  
 8 .  
 40 , 34  
 11 (Mucoepidermoid car-  
 cinoma) 42 (34%) 가 ,  
 4 , 3 (Acinic cell carcinoma) 21  
 , (Malignant mixed tumor) 16 ,  
 (Adenoid cystic carcinoma) 13 ,  
 (Basal cell carcinoma) 7 , (Squamous  
 cell carcinoma) (Adenocarcima) 6 ,  
 (Undifferentiated Carcinoma) 4 ,  
 (Epithelial myoepithelioma) 4 , (Sa-  
 livary duct cell carcinoma) 2 ,  
 124 , (Malignant myoepithelioma), (Ma-  
 lignant schwannoma) (Papillary cy-  
 stadenocarcinoma) 1 (Table 1).  
 가 72 , 가 38 ,  
 13 .  
 38 , 22 가 84 24 (28.5%)  
 , 가 가  
 16 , 7  
 40% , , (Table 1).  
 70 15 (21.4%)  
 ,  
 124 84 .

이하선암종에서 경부 림프절 전이 및 전이의 위험인자에 관한 고찰

**Table 1.** Nodal metastasis according to histopathologic type

Histopathologic type	Incidence of neck mets	% of neck mets.	Incidence of occult neck mets	% of occult neck mets.
Mucoepidermoid carcinoma	6/28	21.4%	7/27	25.9%
Acinic cell carcinoma	1/12	8.3%	1/12	8.3%
Ca.ex pleomorphic adenoma	5/12	41.6%	1/ 9	11.1%
Adenoid cystic carcinoma	0/ 9	0%	0/ 7	0%
Adenocarcinoma	3/ 6	50%	2/ 5	40%
Squamous cell carcinoma	2/ 5	40%	2/ 5	40%
Undifferentiated carcinoma	3/ 4	75%	1/ 1	100%
Basal cell carcinoma	1/ 3	33.3%	0/ 2	0%
Salivary duct cell carcinoma	2/ 2	100%	1/ 1	100%
Others	1/ 3	50%	0/ 1	0%
Total	24/84	28.5%	15/70	21.4%

**Table 2.** Occult metastasis according to histopathologic risk group

Risk group	Histologic type	% of occult mets.
High	Mucoepidermoid carcinoma. (inter/high gr.)	31%
	Adenocarcinoma	40%
	Squamous cell carcinoma	40%
	Undifferentiated carcinoma	100%
	Ca.ex pleomorphic adenoma	11.1%
	Salivary duct cell carcinoma	100%
Total		32.4%
Low	Mucoepidermoid carcinoma. (low gr.)	1.8%
	Acinic cell carcinoma	8.3%
	Basal cell adenocarcinoma	0%
	Adenoid cystic carcinoma	0%
	Total	

Kaplan - Meier  
 plan - Meier 34  
 가 39  
 가 19  
 가  
 (p<0.0001)(Fig. 1).

100%, 가 40% 25.9%  
 (Table 1).  
 32.4%, 9%  
 (Table 2).  
 II가 76.4% 가 level I 17.6%, level  
 III가 5.8%

가 NO  
 가 .  
 8가 가  
 (Table 3), 가 (Table 4).  
 가

10~45% 5-7)  
 가  
 가  
 .7)  
 가 19  
 가 39  
 가  
 가  
 NO  
 가  
 가  
 NO 가  
 가  
 가





- 6) Cuevas SR, Baena LL, Gallegos F. *Risk of nodal metastases from malignant salivary gland tumors related to tumor size and grade of malignancy.* *Eur Arch Otorhinolaryngol* 1995;252:139-42.
- 7) Bhattacharyya N, Fried MP. *Nodal metastasis in major salivary gland cancer.* *Arch Otolaryngol* 2002;128:904-8.
- 8) McGuirt WF. *Management of occult metastatic disease from salivary gland neoplasms.* *Arch Otolaryngol* 1989;115:322-5.
- 9) Kelley DJ, Spiro RH. *Management of the neck in parotid carcinoma.* *Am J Surg* 1996;172:695-7.
- 10) Armstrong JG, Harrison LB, Thaler HT, Klar HF, Fass DE, Zelefsky MJ, et al. *The indications for elective treatment of the neck in cancer of the major salivary glands.* *Cancer* 1992;69:615-9.
- 11) Eneroth CM. *Facial nerve paralysis: A criterion of malignancy in parotid tumors.* *Arch Otolaryngol* 1972;95:300-4.
- 12) Frankenthaler RA, Byers RM, Luna MA, Callender DL, Wolf P, Goeppfert H. *Predicting occult lymph node metastasis in parotid cancer.* *Arch Otolaryngol* 1993;119:517-20.
- 13) Spiro RH, Huvos AG, Strong EW. *Cancer of the parotid gland. A clinicopathologic study of 288 primary cases.* *Am J Surg* 1975;130:452-59.
- 14) Lewis JE, Oslen KD, Weiland LH. *Acinic cell carcinoma: Clinicopathologic review.* *Cancer* 1991;67:172-9.
- 15) Santos IDB, Kowalski LP, Araujo VCD, Logullo AF, Margin J. *Multivariate analysis of risk factors for neck metastases in surgically treated parotid carcinomas.* *Arch Otolaryngol.* 2001;127:56-60.
- 16) Poulsen MG, Tripcony LB, Kynaston B. *Nodal recurrence in primary malignant epithelial tumours of the parotid gland.* *Australas Radiol* 1991;35:169-73.
- 17) Ball AB, Fish S, Thomas JM. *Malignant epithelial parotid tumours: A rational treatment policy.* *Br J Surg* 1995;82:621-3.